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Purpose/Objective: State of the art treatment of locally 
advanced cervical cancer with image guided intensity 
modulated external radiotherapy followed by image guided 
brachytherapy provide good clinical outcome. However, 
there are still 10-15% loco-regional failures and 10-20% who 
experience moderate to severe side effects. In the current 
work we propose to use FDG PET as basis for a short-course 
simultaneous integrated boost (SIB) with external beam 
therapy. This concept may increase tumour control and 
improve tumour shrinkage before brachytherapy. The latter 
may reduce complexity and improve organ sparing at 
brachytherapy. 
Materials and Methods: This study included 10 patients with 
locally advanced cervical cancer all treated with curative 
image guided external beam and brachytherapy. FDG PET/CT 
was obtained prior to therapy for all patients. To explore the 
potential use of PET based dose escalation, a new approach 
was tested in silico. Here, the FDG avid tumour volume was 
dose escalated by intensity modulated radiotherapy from the 
conventional 1.8Gy to 2.8Gy per fraction for the 10 first 
fractions; a short-course SIB. For the remaining 18 external 
beam fractions, standard treatment to the pelvic area is 
followed to a total dose to the PTV and boost volume of 
50.4Gy and 60.4Gy, respectively. For intensity modulation, 
both photons and protons were considered using dual arc 
VMAT and three-field IMPT, respectively. All treatment plans 
were generated using the Eclipse Treatment Planning System 
(v.11, Varian Medical Systems, Palo Alto, CA). 
Results: For the patients included, the PET based boost 
volume had a mean volume of 36 ± 6cm3 as compared to 
average volumes for the GTV and PTV of 69 ± 10cm3 and 1508 
± 55cm3, respectively. The dose escalation was 
straightforward to implement for both VMAT and IMPT, with a 
D98 ≥ 95% for the boost volume being achieved in all cases. 
The sum of the short-course SIB (10 fractions) and the 
subsequent 18 conventional fractions was compared to the 
conventional, 28-fraction non-SIB approach by analysing dose 
volume histograms (Table 1). Only marginal increased doses 
to the relevant organs at risk (OARs) were found for all 
investigated parameters. IMPT had, compared to VMAT, 
reduced OAR doses in the intermediate dose range, but 
showed no relative advantage in dose escalation.  
 
 
Conclusions: The additional 1Gy per fraction to the boost 
volume could be achieved in all patients with only minor 
increase of OAR dose using both VMAT and IMPT. This short-
course approach may prove beneficial in terms of reduced 
impact of anatomical changes during dose escalation and 
allowing time for enhanced tumour shrinkage before 
brachytherapy. Thus, this novel concept may prove clinically 
valuable, in particular for patients with large tumours.  
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Purpose/Objective: To investigate the influence of Monte 
Carlo (MC) dose calculation settings on the proton dose 
distribution. Different phantom geometries and patient cases 
were evaluated with focus on dose calculation accuracy and 
clinical applicability including benchmarking against pencil 
beam (PB) calculations. 
Materials and Methods: MC calculation settings like 
maximum number of particles (5x103-5x105), mean relative 
statistical uncertainty per spot (MRSU = 1-5%) and the MRSU 
threshold (th) (10-60% of maximum dose per spot) for voxels 
included in uncertainty considerations were tested for a 
proton MC algorithm (XiO research version v4.62, Elekta AB, 
Stockholm, Sweden). The clinically used PB algorithm 
including heterogeneity corrections, nuclear interactions and 
energy dependent stopping power ratios1,2 was used for 
benchmarking. All plans were optimized with the PB and 
recalculated using the MC algorithm. 
The phantom consisted of 10 chess pattern cubes of 
10x20x9.6 mm³ with alternating HUs of +1000 (bone) and -
800 (lung) embedded in a water tank. Target structures were 
located within or at varying distances behind the chess 
pattern and irradiated from different directions. A prostate 
(2 opposing beams) and a paranasal sinus (PS) cancer patient 
(3 beams) served as clinical test cases. The results were 
evaluated by means of dose difference maps, γ-index analysis 
(2%/2mm), homogeneity (HI), conformity (CI) and dose 
volume measures. 
1 Soukup et al 2005 PMB 50 
2 Fippel et al 2004 MedPhys 31 
Results: For an accurate dose calculation up to 5x104 
particles were required using a MRSU of 3-5% and up to 5x105 
for under 3%. γ-index analysis (PB dose as reference) for 
plans with a beam entrance angle of 15% revealed a γmean of 
0.5 and γ1% of 3.2, with a failure rate of 13.7% in an area of 3 
cm around the target (Figure 1a). For targets distal to the 
chess pattern the main factor influencing dose differences 
was the distance to the inhomogeneities. The CI was 0.84 for 
the PB and 8.3% less for the MC at a distance of 1 cm, 
irrespectively of the settings. At 3 cm distance negligible 
differences were found between MC and PB.  
Dose calculation for a prostate plan lasted 21 s for the PB 
algorithm. For MC the dose calculation time was higher by a 
factor of 4 (MRSU = 5%) and 78 (MRSU = 1%). D2% and the HI 
increased from 102% to 104% and 0.09 to 0.12 using MC 
instead of PB. These differences showed a decreasing 
tendency for more accurate MC settings. For the PS patient 
the heterogeneous tissue in the brain together with the 
